NCT07677254Recruiting

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Novartis Pharmaceuticals

Start Date

6/30/2026

Completion Date

11/30/2026

Summary

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Eligibility Criteria

Age Range: 18 years to 115 years

Inclusion criteria: * Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. * Male sex at index, where index is the date of initial mCRPC diagnosis. * Age 18 years at index. Exclusion criteria: • None

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Prostatic Neoplasms, Castration-Resistant

Locations

Novartis

East Hanover, New Jersey 07936

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Coordinate outreach and marketing across multiple sites as one effort, plus study-site logistics and tech support.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.